Kilitch Drugs shares closed at 310.65 on February 13, 2025 (NSE) and has given -4.34% returns over the last 6 months. Kilitch Drugs EPS has increased to Rs. 4.28 in December 2024 from Rs. 3.48 in December 2023. EBITDA stands at Rs. 10.48 crore in January 2024 up 41.24% from Rs 7.42 crore in December 2022. The company has a market capitalization of Rs. 1.2 trillion. The shares have given -22.14% returns in the last 12 months, according to NSE data. The stock is trading at a P/E of 16.08 and the share price is at a CAGR of 8.05%. The company’s shares are traded on the Bombay Stock Exchange (BSE) and the NSE’s NSE Alternative Investment scheme is trading on the BSE Midcap index (MSE). The company is a subsidiary of Dion Global Solutions Limited, which has a turnover of $1.1 billion.
